BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 21981434)

  • 1. Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care.
    Martín-Merino E; Johansson S; Morris T; García Rodríguez LA
    Drug Saf; 2011 Nov; 34(11):1061-77. PubMed ID: 21981434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.
    Lapi F; Azoulay L; Niazi MT; Yin H; Benayoun S; Suissa S
    JAMA; 2013 Jul; 310(3):289-96. PubMed ID: 23860987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.
    Gandaglia G; Sun M; Popa I; Schiffmann J; Abdollah F; Trinh QD; Saad F; Graefen M; Briganti A; Montorsi F; Karakiewicz PI
    BJU Int; 2014 Dec; 114(6b):E82-E89. PubMed ID: 24612110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review.
    Liang Z; Zhu J; Chen L; Xu Y; Yang Y; Hu R; Zhang W; Song Y; Lu Y; Ou N; Liu X
    Andrology; 2020 May; 8(3):559-574. PubMed ID: 31743594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men.
    Wang LH; Liu CK; Chen CH; Kao LT; Lin HC; Huang CY
    Andrology; 2016 Jan; 4(1):128-32. PubMed ID: 26711703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk.
    Dragomir A; Touma N; Hu J; Perreault S; Aprikian AG
    J Natl Compr Canc Netw; 2023 Feb; 21(2):163-171. PubMed ID: 36791755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma.
    Lee CH; Huang G; Chan PH; Hai J; Yeung CY; Fong CH; Woo YC; Ho KL; Yiu MK; Leung F; Lau TW; Tse HF; Lam KS; Siu CW
    PLoS One; 2017; 12(2):e0171495. PubMed ID: 28158241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer.
    Azoulay L; Yin H; Benayoun S; Renoux C; Boivin JF; Suissa S
    Eur Urol; 2011 Dec; 60(6):1244-50. PubMed ID: 21908097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
    Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term prognostic impact of cardiovascular comorbidities in patients with prostate cancer receiving androgen deprivation therapy: A population-based competing risk analysis.
    Chan JSK; Lee YHA; Hui JMH; Liu K; Dee EC; Ng K; Liu T; Tse G; Ng CF
    Int J Cancer; 2023 Aug; 153(4):756-764. PubMed ID: 37183319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
    Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
    Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
    Keating NL; O'Malley AJ; Freedland SJ; Smith MR
    J Natl Cancer Inst; 2010 Jan; 102(1):39-46. PubMed ID: 19996060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan.
    Huang WK; Liu CH; Pang ST; Liu JR; Chang JW; Liaw CC; Hsu CL; Lin YC; See LC
    JAMA Netw Open; 2020 Aug; 3(8):e2015189. PubMed ID: 32865575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.
    Wang A; Obertová Z; Brown C; Karunasinghe N; Bishop K; Ferguson L; Lawrenson R
    BMC Cancer; 2015 Nov; 15():837. PubMed ID: 26525985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?].
    Merseburger AS; Sedding D; Hüter K
    Urologe A; 2016 Feb; 55(2):218-25. PubMed ID: 26637324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
    Nguyen C; Lairson DR; Swartz MD; Du XL
    Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis.
    Carneiro A; Sasse AD; Wagner AA; Peixoto G; Kataguiri A; Neto AS; Bianco BA; Chang P; Pompeo AC; Tobias-Machado M
    World J Urol; 2015 Sep; 33(9):1281-9. PubMed ID: 25387877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
    Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
    Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen Deprivation Therapy and the Risk for Inguinal Hernia: An Observational Nested Case Control Study.
    Hermann M; Vikman H; Stattin P; Katawazai A; Gustafsson O; Styrke J; Sandblom G
    Am J Mens Health; 2021; 15(6):15579883211058606. PubMed ID: 34918553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.